Astellas Pharma Inc. (OTCMKTS:ALPMY) Sees Significant Decline in Short Interest

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the recipient of a significant drop in short interest during the month of June. As of June 15th, there was short interest totaling 16,568 shares, a drop of 37.3% from the May 31st total of 26,405 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 474,815 shares, the short-interest ratio is presently 0.0 days.

Astellas Pharma Price Performance

OTCMKTS:ALPMY opened at $13.04 on Thursday. The firm has a market capitalization of $23.60 billion, a price-to-earnings ratio of 12.14 and a beta of 0.07. Astellas Pharma has a 1 year low of $9.22 and a 1 year high of $17.35. The business has a 50 day simple moving average of $14.01 and a 200-day simple moving average of $14.66. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.09 and a quick ratio of 0.84.

Astellas Pharma (OTCMKTS:ALPMY) last released its earnings results on Monday, April 27th. The company reported $0.33 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.14. Astellas Pharma had a return on equity of 24.19% and a net margin of 13.66%.The firm had revenue of $3.38 billion for the quarter, compared to the consensus estimate of $3.28 billion. Equities analysts forecast that Astellas Pharma will post 1.25 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on ALPMY shares. Zacks Research raised shares of Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, June 23rd. Jefferies Financial Group upgraded shares of Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 24th. Two research analysts have rated the stock with a Strong Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy”.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).